Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab-Reference-Cited by-同舟云学术

Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab

Published:2020-12 Issue: Volume:228 Page:122-128
ISSN:0165-2478
Container-title:Immunology Letters
language:en
Short-container-title:Immunology Letters

Author:

Salvati Lorenzo^ORCID,Occhipinti Mariaelena,Gori Leonardo,Ciani Luca,Mazzoni Alessio^ORCID,Maggi Laura,Capone Manuela^ORCID,Parronchi Paola,Liotta Francesco,Miele Vittorio^ORCID,Annunziato Francesco,Lavorini Federico^ORCID,Cosmi Lorenzo^ORCID

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference40 articles.

1. Severe Covid-19;Berlin;N. Engl. J. Med.,2020

2. Mild or moderate Covid-19;Gandhi;N. Engl. J. Med.,2020

3. Compassionate use of remdesivir for patients with severe Covid-19;Grein;N. Engl. J. Med.,2020

4. Dexamethasone in hospitalized patients with Covid-19 - preliminary report;RECOVERY Collaborative Group;N. Engl. J. Med.,2020

5. IDSA Guidelines on the Treatment and Management of Patients with COVID-19;Infectious Diseases Society of America (IDSA),2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin-Converting Enzyme-2 (ACE-2) with Interferon-Induced Transmembrane Protein-3 (IFITM-3) Genetic Variants and Interleukin-6 as Severity and Risk Predictors among COVID-19 Egyptian Population;International Journal of Microbiology;2023-12-21

2. COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development;BioMed Research International;2023-08-29

3. Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ?;Revue des Maladies Respiratoires;2023-01

4. Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?;Drugs;2022-12-12

5. Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence;Expert Review of Anti-infective Therapy;2022-03-07